Medical Devices includes a session from a regulatory expert on how companies can align their research between regions.
GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.
In the ongoing study (NCT06700538), Arrowhead’s candidate, called ARO-INHBE, plus Zepbound, doubled weight loss and tripled ...
Neumora Therapeutics’ oral Alzheimer’s disease agitation drug has shown benefit, reducing agitation, in a Phase Ib trial.
Treatment with the tumour necrosis factor receptor 2 (TNFR2)-targeting monoclonal antibody (mAb) plus Keytruda was also found ...
MetaVia will now be investigating the candidate at two different titration levels in 16-week trials for obesity.
A combination of Eli Lilly’s IL-17 inhibitor Taltz and its weight loss therapy, Zepbound, has been shown to improve outcomes in psoriatic arthritis (PsA) over Taltz monotherapy in a Phase IIIb trial.
Based on the Phase Ib data, Ollin will advance the drug to Phase III trials. Image credit: LuckyStep / Shutterstock.com Ollin Biosciences’ VEGF/Ang2 bispecific antibody has shown superiority over ...
Clinical trial results are expected by end of 2026 to guide dose selection for future ALS/MND and Parkinson’s studies. Credit: Andrzej Rostek / Shutterstock.com. NRG Therapeutics has dosed the first ...
The PRISM process analyses electronic health records, medical histories, diagnoses, and clinical characteristics to determine patient trial eligibility. Credit: Mount Sinai. The Mount Sinai Tisch ...
The decision to end the trial was based on an interim analysis that showed a numerically lower favourable response rate and a numerically higher mortality rate in the opelconazole arm. Image credit: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback